Dr Sanjiv Agarwala discusses the usefulness of MSI and TMB as novel biomarkers for various cancer types. His argument is that the first FDA approval of a therapy based on MSI rather than tumor type makes this biomarker useful, but TMB is not yet ready for “prime time.”
Stay up to date with personalized medicine by subscribing to recieve the free VBCC print publication or weekly e‑Newsletter.